Genencor Identifies Structure of a Novel Fungal Cellulase

Findings to Lead to the Development of Enzymes for More

Efficient Industrial Processes



Apr 30, 2001, 01:00 ET from Genencor International, Inc.

    PALO ALTO, Calif., April 30 /PRNewswire/ --
 Genencor International, Inc. (Nasdaq:   GCOR) announced today the publication,
 in a peer-reviewed journal, of results describing the structure of a
 commercially important fungal cellulase, Cel12A (EG3).  This work will enable
 Genencor to develop improved novel cellulase enzymes designed to enhance the
 efficiency of industrial processes including the production of detergents,
 textiles, food, paper and fuel alternatives such as ethanol.
     The paper, published in the Journal of Molecular Biology, entitled
 "The X-ray crystal structure of the Trichoderma reesei family 12 endoglucanase
 3 (Cel12A) at 1.9A," describes results from an international collaboration
 between scientists at Genencor, and both Uppsala University and the Swedish
 University of Agricultural Sciences in Uppsala, Sweden.  Using X-ray
 crystallography, the scientists determined the specific structural features of
 the Cel12A protein that provide important insight into the mechanism of action
 of the protein.
     "This publication further validates Genencor's in-depth expertise in
 fungal biology, protein chemistry, and crystallography," commented Michael
 Arbige Ph.D., Senior Vice President of Research and Development. "Such core
 competencies are an integral part of our i-biotech(TM) solution, which
 integrates our full suite of technologies, facilitating the rapid development
 of more effective and safer biologically engineered materials for the
 consumer, industrial and health care markets."
     Cellulases are a commercially important class of enzymes found in fungal
 and bacterial microorganisms that utilize plant matter as one of their primary
 carbon sources. They are responsible for the degradation of plant cell walls
 and provide a fast and effective means of releasing important fermentable
 sugars from plant matter. By understanding the precise locations of amino
 acids within the protein, Genencor can incorporate this information into its
 molecular evolution and design platform to accelerate the natural evolutionary
 process and genetically engineer, and optimize, biomaterials in more
 advantageous ways. Furthermore, the integration of these data into Genencor's
 immunology platform allows assessment and elimination of potential allergenic
 risk from newly created biomaterials.  Novel enzymes derived from these
 processes will, for example, be evaluated to enhance the technology for
 ethanol fuel production from cellulose biomass.
 
     About Genencor
     Genencor International is a diversified biotechnology company that
 develops and delivers innovative products into the health care, agriculture,
 and industrial and consumer markets. Using an integrated set of technology
 platforms, Genencor's products deliver innovative and sustainable solutions to
 many of the problems of everyday life.
     Genencor was established in 1982 as a joint venture between Genentech Inc.
 and Corning Incorporated. Since its founding, Genencor has grown to become a
 leading biotechnology company, with over $315 million in annual revenues, more
 than 250 biotechnology products in commerce, and over 3,400 owned and licensed
 patents and applications. Genencor, with more than 1,500 employees worldwide,
 has principal offices in Palo Alto, California; Rochester, New York; and
 Leiden, the Netherlands.
 
     Except for the historical information contained herein, the matters
 discussed in this press release may contain forward-looking statements which
 involve risks and uncertainties, including significant fluctuations in product
 performance depending on factors such as a dependence on the efforts of third
 parties, a new and uncertain technology employed by Genencor and its uncertain
 application to new business ventures, dependence on intellectual property
 rights, the competitive nature of Genencor's industry and risks of
 obsolescence of certain technology.  Actual results may differ materially from
 those projected. Forward-looking statements represent the judgment of Genencor
 as of the date of this release. Genencor disclaims, however, any intent or
 obligation to update any forward-looking statements.
 
                     MAKE YOUR OPINION COUNT -- Click Here
                http://tbutton.prnewswire.com/prn/11690X57497366
 
 

SOURCE Genencor International, Inc.
    PALO ALTO, Calif., April 30 /PRNewswire/ --
 Genencor International, Inc. (Nasdaq:   GCOR) announced today the publication,
 in a peer-reviewed journal, of results describing the structure of a
 commercially important fungal cellulase, Cel12A (EG3).  This work will enable
 Genencor to develop improved novel cellulase enzymes designed to enhance the
 efficiency of industrial processes including the production of detergents,
 textiles, food, paper and fuel alternatives such as ethanol.
     The paper, published in the Journal of Molecular Biology, entitled
 "The X-ray crystal structure of the Trichoderma reesei family 12 endoglucanase
 3 (Cel12A) at 1.9A," describes results from an international collaboration
 between scientists at Genencor, and both Uppsala University and the Swedish
 University of Agricultural Sciences in Uppsala, Sweden.  Using X-ray
 crystallography, the scientists determined the specific structural features of
 the Cel12A protein that provide important insight into the mechanism of action
 of the protein.
     "This publication further validates Genencor's in-depth expertise in
 fungal biology, protein chemistry, and crystallography," commented Michael
 Arbige Ph.D., Senior Vice President of Research and Development. "Such core
 competencies are an integral part of our i-biotech(TM) solution, which
 integrates our full suite of technologies, facilitating the rapid development
 of more effective and safer biologically engineered materials for the
 consumer, industrial and health care markets."
     Cellulases are a commercially important class of enzymes found in fungal
 and bacterial microorganisms that utilize plant matter as one of their primary
 carbon sources. They are responsible for the degradation of plant cell walls
 and provide a fast and effective means of releasing important fermentable
 sugars from plant matter. By understanding the precise locations of amino
 acids within the protein, Genencor can incorporate this information into its
 molecular evolution and design platform to accelerate the natural evolutionary
 process and genetically engineer, and optimize, biomaterials in more
 advantageous ways. Furthermore, the integration of these data into Genencor's
 immunology platform allows assessment and elimination of potential allergenic
 risk from newly created biomaterials.  Novel enzymes derived from these
 processes will, for example, be evaluated to enhance the technology for
 ethanol fuel production from cellulose biomass.
 
     About Genencor
     Genencor International is a diversified biotechnology company that
 develops and delivers innovative products into the health care, agriculture,
 and industrial and consumer markets. Using an integrated set of technology
 platforms, Genencor's products deliver innovative and sustainable solutions to
 many of the problems of everyday life.
     Genencor was established in 1982 as a joint venture between Genentech Inc.
 and Corning Incorporated. Since its founding, Genencor has grown to become a
 leading biotechnology company, with over $315 million in annual revenues, more
 than 250 biotechnology products in commerce, and over 3,400 owned and licensed
 patents and applications. Genencor, with more than 1,500 employees worldwide,
 has principal offices in Palo Alto, California; Rochester, New York; and
 Leiden, the Netherlands.
 
     Except for the historical information contained herein, the matters
 discussed in this press release may contain forward-looking statements which
 involve risks and uncertainties, including significant fluctuations in product
 performance depending on factors such as a dependence on the efforts of third
 parties, a new and uncertain technology employed by Genencor and its uncertain
 application to new business ventures, dependence on intellectual property
 rights, the competitive nature of Genencor's industry and risks of
 obsolescence of certain technology.  Actual results may differ materially from
 those projected. Forward-looking statements represent the judgment of Genencor
 as of the date of this release. Genencor disclaims, however, any intent or
 obligation to update any forward-looking statements.
 
                     MAKE YOUR OPINION COUNT -- Click Here
                http://tbutton.prnewswire.com/prn/11690X57497366
 
 SOURCE  Genencor International, Inc.